Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M25-287 Telisotuzumab Adizutecan plus Osimertinib in First-Line EGFR-Mutated NSCLC
jRCT2031250209Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of telisotuzumab adizutecan and osimertinib in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc. Started Sep 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250209.